Skip to main content
Clinical Trials/NCT06449079
NCT06449079
Not yet recruiting
Not Applicable

Predictive Risk Algorithm for Development of Right Ventricular Pacing Induced Cardiomyopathy - a Step Towards Personalized Pacemaker Lead Deployment

Guy's and St Thomas' NHS Foundation Trust3 sites in 1 country10,000 target enrollmentJuly 30, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart Failure
Sponsor
Guy's and St Thomas' NHS Foundation Trust
Enrollment
10000
Locations
3
Primary Endpoint
Primary aim
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

Development of pacing induced cardiomyopathy (PICM) is correlated to a high morbidity as signified by an increase in heart failure admissions and mortality. At present a lack of data leads to a failure to identify patients who are at risk of PICM and would benefit from pre-selection to physiological pacing. In the light of the foregoing, there is an urgent need for novel non-invasive detection techniques which would aid risk stratification, offer a better understanding of the prevalence and incidence of PICM in individuals with pacing devices and the contribution of additional risk factors.

Detailed Description

Retrospective review of patient characteristics including 12 lead resting electrocardiograms and imaging data (CMR, CT, echo, CXR and fluoroscopy of pacing leads) of patients with right sided ventricular pacing lead due to symptomatic bradycardia, who developed pacing induced cardiomyopathy (or need for CRT upgrade) versus patients who did not using supervised machine learning methods. Development of personalised predictive pacing algorithm to improve right ventricular lead placement, such as conduction system pacing or pre-emptive implantation of an additional left ventricular lead to prevent left ventricular dilatation and pacemaker-induced cardiomyopathy (PICM) with heart failure (left ventricular ejection fraction \<50% by Simpson method), hospitalisation or death with the use of the retrospective patient data through machine learning.

Registry
clinicaltrials.gov
Start Date
July 30, 2024
End Date
October 30, 2026
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • All patients who received a pacing device (VVI, DDD, ICD, leadless pacemaker) from the GSTT/RBH/KCH/ICH database in the last 10 years (from 01/01/2014)
  • All patients who are \>18 years old.
  • Male and Female

Exclusion Criteria

  • Patients who did not receive a pacing device (VVI, DDD, ICD, leadless pacemaker)
  • All patients \<18 years old
  • Patients with congenital heart disease
  • Patients who have received artificial heart valves or underwent cardiac bypass surgery
  • Patients who did not have an echocardiogram after receiving a pacing device

Outcomes

Primary Outcomes

Primary aim

Time Frame: 2.5 years

Number of risk factors in participants who developed pacing induced cardiomyopathy

Secondary Outcomes

  • Tertiary aim(2.5 years)
  • Quarternary aim(2.5 years)
  • Quinary aim(2.5 years)
  • Septenary aim(2.5 years)
  • Secondary aim(2.5 years)
  • Senary aims(2.5 years)

Study Sites (3)

Loading locations...

Similar Trials